Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
Neurotech International (NTI) has flagged to its shareholders that the FDA hasn’t…
Neurotech International Limited (ASX:NTI)
About Neurotech International Limited
Key Information
NTI In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 15/11/2024 | Price Sensitive PS Positive Genomic Effects of NTI164 in PANDAS/PANS Patients | 211KB | 1.2K |
| 12/11/2024 | New Scientific Publication Highlights Benefits of NTI164 | 159.89KB | 273 |
| 11/11/2024 | Proposed issue of securities - NTI | 19.83KB | 228 |
| 11/11/2024 | Price Sensitive PS Neurotech Appoints Dr Anthony Filippis as MD/CEO | 118.54KB | 1.5K |
| 23/10/2024 | Price Sensitive PS Quarterly Activities/Appendix 4C Cash Flow Report | 410.52KB | 2.3K |
| 16/10/2024 | Notice of Annual General Meeting/Proxy Form | 483.01KB | 755 |
| 08/10/2024 | Becoming a substantial holder | 120.58KB | 1.1K |
| 04/10/2024 | Price Sensitive PS US FDA Response to Orphan Drug Request in PANDAS/PANS | 103.42KB | 5.8K |